Cogstate Joins New Collaboration of Global Health Leaders to Define Numerical Core Metrics for Alzheimer’s Disease
The neuroscience technology company Cogstate Ltd. (ASX.CGS) today announced that it has joined the Digital Medicine Society (DiMe) Project to Develop Digital Measures for Alzheimer’s Disease and Related Dementias (ADRD). Cogstate joins other DiMe partners including Biogen, Eli Lilly, Eisai, Merck, Alzheimer’s Drug Discovery Foundation (ADDF) and many more, all with the common goals of defining digital health measurement to accelerate the developing new therapies and improving care management for patients and families affected by Alzheimer’s disease (AD).
AD is a growing public health epidemic, with 47 million people affected and cases expected to double every 20 years. The costs to individuals, families and society are enormous. Increasingly, digital tools have the potential to provide more objective and accurate information about the impact of dementia-related illnesses on patients and to better assess the effects of therapeutic interventions.
DiMe assembled a project team of world leaders to define a set of core numerical measures in SARD to bring consensus, consistency and efficiency to how symptoms of SARD are measured to improve drug development and clinical care.
“Cogstate is a pioneer in the use of digital technologies to optimize the measurement of cognitive health in Alzheimer’s disease for the development of new drugs and for earlier and more accurate diagnosis in health care,” said said Brad O’Connor, CEO of Cogstate. “We look forward to working with DiMe and the other members of the project to advance this important work in the fight against this devastating global public health crisis.”
“It is a pleasure to have Cogstate in our cohort of leading companies working to build consensus on a core set of numerical measures for Alzheimer’s disease and related dementias,” said Christina Marasco, PhD, Program Manager, DiMe. “The meeting of this group is a tremendous opportunity to accelerate the development of new effective therapies and to improve care management.”
Cogstate Ltd (ASX: CGS) is a leading neuroscience technology company that optimizes brain health assessments to advance new drug development and enable earlier clinical insights into health. Cogstate technologies provide fast, reliable and highly sensitive computer-based cognitive testing and support electronic clinical outcome assessment (eCOA) solutions to replace costly, error-prone paper-based assessments with real-time data capture. For more than 20 years, Cogstate has proudly supported the cutting-edge research needs of biopharmaceutical companies and academic institutions, as well as the clinical care needs of physicians and patients around the world. For more information, visit Cogstate.com or follow us on LinkedIn and Twitter.
About the Society for Digital Medicine
The Digital Medicine Society (DiMe) is the professional society serving the digital medicine community, driving scientific advancement and wide acceptance of digital medicine to improve public health. At DiMe, our commitment to fully integrating experts from all disciplines that make up digital medicine is unwavering. From regulators to hackers, ethicists to engineers, and clinicians to citizen scientists, we are proud to welcome all experts committed to ensuring that digital medicine realizes its full potential to improve human health.
Back to news